Group 1 - In 2025, out of 650 comparable QDII funds, 619 funds saw an increase in net value, representing 95.2% of the total, while 31 funds experienced a decline [1] - The top-performing fund, Huatai Fuhong Hong Kong Advantage Selection Mixed (QDII) A/C, achieved a remarkable growth of 114.19% and 113.83% respectively [1] - The fund's investment strategy focuses on innovative pharmaceuticals with global competitiveness and high-barrier equipment and consumables [1] Group 2 - The current fund manager of Huatai Fuhong is Zhang Wei, who has extensive experience in the pharmaceutical sector [2] - Six other QDII funds recorded growth exceeding 80%, with four of them managed by E Fund Management, all surpassing 85% growth [2] - The top holdings of these funds include major companies like TSMC, NVIDIA, Google, and Alibaba [2] Group 3 - There are 26 QDII funds with monthly growth rates between 60% and 80%, with the largest being GF Zhongzheng Hong Kong Innovative Medicine ETF (QDII), which had a growth of 66.65% [3] - The Fuguo Blue Chip Selected Stock (QDII) in USD also showed significant growth of 67.99% [4] Group 4 - The bottom-performing QDII funds in 2025 were primarily those focused on oil and gas products, with 10 funds declining over 10% [5] - E Fund Management had four products leading the decline, with losses ranging from 11.64% to 13.59% [5]

Core Viewpoint - The newly launched Hong Kong Stock Connect Medical ETF, Huabao (159137), is expected to perform actively due to the rising interest in the medical sector and favorable market conditions, coinciding with the recent recovery of the Hong Kong and A-share medical sectors at the beginning of 2026 [1][14]. Group 1: ETF Launch and Market Context - The Hong Kong Stock Connect Medical ETF Huabao (159137) was established on December 31, 2025, and began trading on January 12, 2026 [1][15]. - The Shanghai Composite Index has recently shown a rare "sixteen consecutive days of gains," surpassing the 4100-point mark, indicating high investor enthusiasm [1][14]. - The Hong Kong Stock Connect Medical Theme Index has increased by 14.25% from January 1 to January 9, 2026, and had an annual increase of 48.20% in 2025, reflecting a significant recovery in the medical sector [1][15]. Group 2: ETF Composition and Investment Focus - The ETF tracks the CSI Hong Kong Stock Connect Medical Theme Index, covering four major areas: CXO, medical business and services, medical devices, and biopharmaceuticals, with over 80% of its weight concentrated in leading companies in CXO, internet healthcare, and high-end medical devices [2][15]. - More than 85% of the ETF's components are "Hong Kong exclusive" stocks, including unique offerings like JD Health and Alibaba Health, which provide investors with significant opportunities in the Hong Kong medical sector [2][15]. Group 3: Market Potential and Valuation - The Hong Kong medical sector is characterized as a "golden track" with substantial market potential, driven by an aging population and increasing healthcare demand, supported by a growing GDP per capita [4][19]. - The CSI Hong Kong Stock Connect Medical Theme Index is currently at a historical low, with a drop of over 65% from its peak in 2021, and a price-to-earnings ratio (TTM) of 29.43, which is below 65% of its historical range [6][19]. - The index's configuration offers a compelling cost-performance ratio, making the ETF a noteworthy investment tool for investors [6][19].

Core Insights - The approval of Zeshuo Pharmaceutical's injection of human thyroid-stimulating hormone beta (Zesuning) marks a significant milestone as it becomes China's first innovative product approved for precise assessment post-surgery for differentiated thyroid cancer [1][2] - The Chinese innovative drug industry is experiencing robust growth, with multiple new drugs receiving approval since the beginning of 2026, including innovative drugs from companies like Hengrui Medicine and BeiGene [1][2] - The National Medical Products Administration (NMPA) is enhancing support for innovative drugs, focusing on new mechanisms and targets, and aims to facilitate the "China first launch" of innovative drugs [3][4] Company Developments - Hengrui Medicine's innovative drug, the dual-specific antibody fusion protein Ruilafuzumab α injection, has been approved as the world's first anti-PD-L1/TGF-βRII dual-specificity antibody fusion protein for advanced gastric cancer [1][2] - BeiGene's innovative drug, Sotorasib tablets, has received conditional approval for treating chronic lymphocytic leukemia/small lymphocytic lymphoma and is the first and only BCL2 inhibitor approved for treating mantle cell lymphoma in China [2] - The approval of multiple innovative drugs reflects a significant increase in the number of innovative drugs approved in China, with 76 approved in 2025, surpassing the 48 approved in 2024 [2] Industry Trends - Approximately 20 major new drugs are expected to receive approval in 2026, covering various therapeutic areas such as oncology, infectious diseases, rare diseases, autoimmune diseases, and neurological disorders [3] - The Chinese innovative drug industry is transitioning from a follower to a competitor, with many domestic companies accelerating the development and market entry of groundbreaking innovative drugs [2][3] - The NMPA is implementing reforms to enhance the drug approval process, including the introduction of a data protection system for drug trials and a market exclusivity system for pediatric and rare disease medications [4][5] Policy Support - The NMPA is set to provide comprehensive support across the entire chain of communication, clinical trials, registration, and review processes for innovative drugs [4] - The new medical insurance directory has been implemented, facilitating the inclusion of innovative drugs in hospitals, which alleviates initial payment challenges for high-value innovative drugs [4] - The NMPA is also optimizing the review process for urgently needed foreign drugs, encouraging global simultaneous research and application in China [4][5]

Investment Rating - The industry investment rating is "Positive" (maintained) [2] Core Insights - The pharmaceutical and biotechnology sector has shown a positive trend, with a 7.81% increase in early January 2026, outperforming the CSI 300 index by 5.03 percentage points [8][34] - Arrowhead's small RNA therapies ARO-INHBE and ARO-ALK7 have demonstrated promising early clinical data for obesity treatment, indicating a potential new era in weight management therapies [6][15][24] Summary by Sections Industry Performance - The pharmaceutical and biotechnology sector has risen by 7.81% in the first week of January 2026, ranking 6th among 31 sub-industries [8][34] - The hospital sector experienced the highest increase at 13.92%, while the traditional Chinese medicine sector had the lowest increase at 2.89% [37] Clinical Data Insights - ARO-INHBE showed a 9.9% average reduction in visceral fat at week 16 in a single-agent treatment for obesity with T2DM, with a 37.8% reduction in liver fat compared to baseline [6][15] - In combination therapy with Tirzepatide, ARO-INHBE achieved nearly double the weight loss effect compared to Tirzepatide alone, with significant reductions in total fat and visceral fat [7][16] - ARO-ALK7 demonstrated an 88% average degradation rate of ALK7 mRNA, with a 13.6% reduction in visceral fat, indicating superior efficacy compared to ARO-INHBE [24][29] Market Positioning - There is an accelerated focus on the INHBE and ALK7 targets by domestic and international companies, with several products entering clinical stages [31][33] - The competitive landscape for ALK7 is relatively favorable, with fewer products in clinical stages compared to INHBE, which has multiple candidates in development [31][33]

Core Viewpoint - The Chinese innovative drug industry is entering a new phase of "earning dollars," prompting public funds to rapidly launch new pharmaceutical funds in early 2026 [1][3]. Group 1: Fund Launches and Market Activity - In the first week of 2026, there has been a surge in new fund launches focused on innovative drugs, with significant investments directed towards the Hong Kong pharmaceutical sector [3][4]. - Notable new products include the Hua Bao Hong Kong Medical Theme ETF, which raised 331 million yuan and quickly built a stock position of 14.70% [3]. - The Fu Guo Hang Seng Biotechnology ETF also launched, raising over 320 million yuan and focusing on leading Hong Kong pharmaceutical companies [3][4]. Group 2: Performance and Demand for Pharmaceutical Funds - The strong performance of Hong Kong pharmaceutical funds in 2025 has heightened demand from both institutional and retail investors for new pharmaceutical fund offerings [6][7]. - The Hong Kong pharmaceutical theme funds delivered impressive returns in 2025, with some achieving over 113% cumulative returns, significantly influencing investor interest [6][7]. - Despite a market correction at the end of 2025, this has created an opportunity for new funds to lock in low-priced assets, leading to a rebound in fund net values [6]. Group 3: Future Expectations and Market Trends - The innovative drug sector is expected to experience a "performance verification phase" in 2026, with key indicators such as revenue from business development (BD) payments and the sales growth of core innovative drugs being closely monitored [9]. - Fund managers anticipate that 2026 will see more products entering large-scale global Phase III clinical trials, which could enhance market confidence and drive up the global value of innovative drugs [8][9]. - The industry is viewed as transitioning from following innovation to achieving global commercialization, with expectations that more Chinese innovative drug companies will realize overseas commercialization by 2027, leading to a systematic revaluation of the sector [9].

Core Viewpoint - The Chinese innovative pharmaceutical industry is entering a "dollar-earning" phase, prompting public funds to rapidly launch new medical funds in early 2026 [2][3]. Group 1: Fund Launches and Market Trends - In the first week of 2026, there has been a surge in new fund launches focused on innovative pharmaceuticals, driven by the industry's transition to global commercialization [2][3]. - Public funds are increasingly targeting the Hong Kong pharmaceutical sector, with new products like the Huabao Hong Kong Medical Theme ETF and the Fuguo Hang Seng Biotechnology ETF being launched to capitalize on this trend [3][4]. - The demand for innovative pharmaceutical funds is being fueled by the strong performance of Hong Kong pharmaceutical funds in 2025, which saw significant returns, such as the Huatai-PineBridge Hong Kong Advantage Select QDII fund achieving a cumulative return of 113% [5][6]. Group 2: Investment Strategies and Expectations - Fund managers believe that the global commercialization of innovative drugs is a key characteristic for the emergence of industry giants, and this transition is expected to lead to a new valuation phase for the sector [2][7]. - The innovative pharmaceutical sector is anticipated to experience a "performance verification phase" in 2026, with key indicators such as the realization of upfront payments and the sales growth of core innovative drugs being closely monitored [8]. - The market is expected to see a systematic valuation reshaping starting in 2027, as more Chinese innovative pharmaceutical companies achieve overseas commercialization [8].

| 申万菱信医药先锋股票A(005433) | | | | --- | --- | --- | | 单位净值(2026-01-08) | 累计净值 | | | 0.4934 0.12% | 0.4934 | | | 近1月:2.03% | 沂3月: -6.46% | 沂6日: -9 13% | | 沂1年:-6.52% | 沂3年:-38.88% | 成立来:-50.66% | | 申万菱信医药先锋股票C(015171) | | | | 单位净值(2026-01-08) | 累计净值 | | | 0.4847 0.12% | 0.4847 | | | 沂1月:1.98% | 近3月: -6.77% | 近6日: -9.52% | | 沂1年: - 7.09% | 近3年:-39.74% | 成立来:-40.17% | 来源：同花顺 中国经济网北京1月9日讯 据同花顺数据显示，在刚过去的2025年，申万菱信医药先锋股票C、申万 菱信医药先锋股票A以-17.81%、-17.29%的表现垫底全年普通股票型基金业绩排行榜。 (责任编辑：康博) 资料显示，申万菱信医药先锋股票A/C分别成立于2020年11月和2022年 ...

Group 1 - The core viewpoint of the news highlights the performance and growth of the Tianhong Innovation Drug ETF (517380), which has seen significant trading activity and net inflows, indicating strong investor interest in the innovative pharmaceutical sector [1] - As of January 8, the Tianhong Innovation Drug ETF reached a new high with a total scale of 1.597 billion yuan and 1.980 billion shares outstanding, reflecting robust market demand [1] - The ETF tracks the Hang Seng Shanghai-Shenzhen Hong Kong Innovation Drug Select 50 Index (HSSSHID), which includes a diverse selection of 50 leading innovative pharmaceutical companies, with a composition of 40% Hong Kong stocks and 60% A-shares [1] Group 2 - Notable achievements in the innovative pharmaceutical sector include Shiyao Group's R&D expenses of 4.185 billion yuan for the first three quarters of 2025, focusing on ADC, GLP-1, and small nucleic acid pipelines, with total authorized amounts exceeding 9.7 billion USD [2] - BeiGene is projected to achieve a profit of 200 million USD in 2025, with expectations of reaching 600-800 million USD in 2026, as several solid tumor drugs enter critical clinical stages [2] - Three Life Sciences has partnered with Pfizer for a 6 billion USD dual antibody licensing deal, receiving an upfront payment of 1.4 billion USD, with 20 clinical studies planned for 2026 [2]

Group 1 - The core idea emphasizes the importance of leveraging capital markets for companies to overcome development bottlenecks and expand globally [1][2] - The article highlights the significance of entrepreneurs' vision and spirit in driving market vitality and the need for companies to broaden their horizons for long-term success [1][2] - It discusses the evolution of Chinese companies from merely exporting products to engaging in deep capital and technology cooperation on a global scale [2][3] Group 2 - The article presents two distinct paths for internationalization: Longyan Automobile's global production capabilities and Hebei Steel Group's capital-driven approach to link global resources [2][3] - It asserts that the capital market acts as an "accelerator" for corporate growth, necessitating that modern entrepreneurs not only manage operations but also effectively utilize capital [3][4] - The development of a multi-tiered capital market in China is described as a vibrant ecosystem that supports various types of enterprises at different stages of growth [3][5] Group 3 - The article emphasizes the need for entrepreneurs to break geographical and cognitive boundaries, integrating into broader industrial frameworks and enhancing their capabilities in international market dynamics [2][4] - It notes that Hebei's capital market has seen significant growth, with 123 listed companies and direct financing exceeding 100 billion yuan by the end of 2025 [5] - The ongoing Hebei Capital Market Lecture Series is positioned as a platform for continuous learning and dialogue, aimed at helping entrepreneurs expand their perspectives and improve their operational capabilities [5][6]

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the advancements in the small nucleic acid drug sector, particularly focusing on companies like Wave Life Sciences and Arrowhead Pharmaceuticals, which have shown promising data in weight loss and fat reduction therapies [1][4][5]. Core Insights and Arguments - **Advantages of Small Nucleic Acid Drugs**: These drugs demonstrate long-lasting effects, improved safety by reducing the dosage of GLP-1 drugs, and the ability to achieve high-quality weight loss by specifically targeting visceral fat while preserving lean body mass [1][5]. - **Clinical Developments**: Key catalysts for 2026 include advancements in major indications such as severe hypertriglyceridemia (SHTG), cardiovascular outcomes related to LPA, and IgA nephropathy. Arrowhead's OX7 data is expected to show significant clinical changes in humans [1][8]. - **Market Position of Chinese Companies**: Chinese firms are leveraging engineering advantages to enhance specificity and delivery efficiency, positioning themselves to develop best-in-class molecules, particularly in non-liver diseases [1][9]. - **Emerging Targets in Hyperlipidemia**: New targets like LP(a) are gaining attention, with major Chinese pharmaceutical companies like Hengrui and Shiyao licensing oral small molecule LP(a) inhibitors to multinational corporations for approximately $2 billion each [3][20]. Additional Important Content - **Recent Progress in Small Nucleic Acid Research**: Recent data from Wave Life Sciences and Arrowhead Pharmaceuticals confirm the efficacy of small nucleic acid drugs in weight loss and fat reduction, with significant results observed in clinical trials [4][24]. - **Commercialization and Development Trends**: The small nucleic acid drug sector has seen a resurgence since 2016, with successful commercialization efforts leading to substantial market valuations, such as Alnylam's peak market cap of $60 billion [17][18]. - **Challenges in Delivery Systems**: While advancements have been made in delivery systems, many remain in early stages, indicating a need for further innovation to enhance efficacy and safety in non-liver delivery systems [16][24]. - **Trends in MNC Transactions**: There is a notable trend of large pharmaceutical companies showing interest in early-stage small nucleic acid drugs, with significant transaction values even at the preclinical stage, indicating strong market confidence [19]. This summary encapsulates the critical developments and insights from the conference call, highlighting the potential and challenges within the small nucleic acid drug industry.